Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
3-year results show that patients who underwent low-risk aortic valve replacement continue to report lower rates of all-cause mortality and stroke with TAVI compared to surgery
Read Full NewsMerck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.
New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.
New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.
5 FDA Headlines You Missed in November 2025
1.
Cardiorespiratory fitness lowers the risk of colon, lung, and prostate cancer in MEN and lowers mortality from these diseases.
2.
Psychedelic Therapy Tied to Reduced Depression, Anxiety.
3.
Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation
4.
Appropriate New Monoclonal for Immunocompromised Individuals to Prevent COVID-19.
5.
Can certain food cravings predict a cancer diagnosis up to three months before other symptoms appear?
1.
A Closer Look at MCV Modules: Features, Functions, and Benefits
2.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
3.
HPV and Immunotherapy in Cancer Survivorship: National Cancer Survivors Day Review
4.
Navigating the Complexities of Melanoma Staging: A Comprehensive Guide
5.
HSC Failure in Fanconi Anemia: Mechanisms, Models, and Emerging Therapeutic Pathways
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part XV
2.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
3.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
4.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
5.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge